Jeffrey G. Supko

22.3k total citations · 2 hit papers
192 papers, 16.1k citations indexed

About

Jeffrey G. Supko is a scholar working on Molecular Biology, Oncology and Genetics. According to data from OpenAlex, Jeffrey G. Supko has authored 192 papers receiving a total of 16.1k indexed citations (citations by other indexed papers that have themselves been cited), including 94 papers in Molecular Biology, 83 papers in Oncology and 46 papers in Genetics. Recurrent topics in Jeffrey G. Supko's work include Glioma Diagnosis and Treatment (37 papers), Cancer therapeutics and mechanisms (36 papers) and Cancer Treatment and Pharmacology (29 papers). Jeffrey G. Supko is often cited by papers focused on Glioma Diagnosis and Treatment (37 papers), Cancer therapeutics and mechanisms (36 papers) and Cancer Treatment and Pharmacology (29 papers). Jeffrey G. Supko collaborates with scholars based in United States, Canada and Spain. Jeffrey G. Supko's co-authors include Thomas J. Lynch, Frank G. Haluska, Daniel A. Haber, David N. Louis, David C. Christiani, Brian W. Brannigan, Sara M. Haserlat, Raffaella Sordella, Sarada Gurubhagavatula and Patricia L. Harris and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Jeffrey G. Supko

188 papers receiving 15.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib

2004 8.9k citations Jeffrey G. Supko et al. profile →
A phase I/II trial of hydroxychloroquine in conjunction with radiation therapy and concurrent and adjuvant temozolomide in patients with newly diagnosed glioblastoma multiforme

2014 409 citations Jeffrey G. Supko, Stuart A. Grossman et al. profile →

Peers

Countries citing papers authored by Jeffrey G. Supko

Since Specialization

Citations

This map shows the geographic impact of Jeffrey G. Supko's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jeffrey G. Supko with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jeffrey G. Supko more than expected).

Fields of papers citing papers by Jeffrey G. Supko

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jeffrey G. Supko. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jeffrey G. Supko. The network helps show where Jeffrey G. Supko may publish in the future.

Co-authorship network of co-authors of Jeffrey G. Supko

This figure shows the co-authorship network connecting the top 25 collaborators of Jeffrey G. Supko. A scholar is included among the top collaborators of Jeffrey G. Supko based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jeffrey G. Supko. Jeffrey G. Supko is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial 2024 ·Carolina Digital Repository (University of North Carolina at Chapel Hill) ·Jesús G. Berdeja, Min Yang, Noopur Raje, Edward N. Libby, Simon S. Jones, Nicole Birrer, David Tamang, Peter M. Voorhees, Andrew J. Yee, Robert J Markelewicz, Jeffrey G. Supko, William Bensinger, Jill N. Burke, Ellen Wallace, Paul G. Richardson, Catherine Wheeler	0
2	Severe Lactic Acidosis Complicated by Insulin-Resistant Hyperosmolar Hyperglycemic Syndrome in a Patient With Metastatic Breast Cancer Undergoing AKT-Inhibitor Therapy 2022 ·JCO Precision Oncology ·Maria Stamou, (unknown), Seth A. Wander, Jeffrey G. Supko, Dejan Juric, Aditya Bardia, Deborah J. Wexler	0
3	A Phase I Study of Pelabresib (CPI-0610), a Small-Molecule Inhibitor of BET Proteins, in Patients with Relapsed or Refractory Lymphoma 2022 ·Cancer Research Communications ·(unknown), Jeffrey G. Supko, Michael B. Maris, Ian W. Flinn, André Goy, Anas Younes, (unknown), Adrian M. Senderowicz, (unknown), (unknown), Gozde Colak, Patrick Trojer, Jeremy S. Abramson	23
4	Dual Blockade of c-MET and the Androgen Receptor in Metastatic Castration-resistant Prostate Cancer: A Phase I Study of Concurrent Enzalutamide and Crizotinib 2020 ·Clinical Cancer Research ·Abhishek Tripathi, Jeffrey G. Supko, Kathryn P. Gray, (unknown), Meredith M. Regan, Mary‐Ellen Taplin, Atish D. Choudhury, Mark M. Pomerantz, Joaquim Bellmunt, Channing Yu, Zijie Sun, Sandy Srinivas, Philip W. Kantoff, Christopher J. Sweeney, Lauren C. Harshman	13
5	A Multicenter Phase II Study Using a Dose Intensified Pegylated-Asparaginase Pediatric Regimen in Adults with Untreated Acute Lymphoblastic Leukemia: A DFCI ALL Consortium Trial 2015 ·Blood ·Daniel J. DeAngelo, Kristen E. Stevenson, Donna Neuberg, Lewis B. Silverman, Karen K. Ballen, Julie Asch, Yasser Abou Mourad, Kristjan Paulson, Matthew D. Seftel, David Avigan, Julie Bergeron, Stephen Couban, William Blum, John M. Storring, Martha Wadleigh, David P. Steensma, Jeffrey G. Supko, Stephen E. Sallan, Richard M. Stone	37
6	Multicenter Phase II Study of Tivozanib (AV-951) and Everolimus (RAD001) for Patients With Refractory, Metastatic Colorectal Cancer 2013 ·The Oncologist ·Brian M. Wolpin, Kimmie Ng, Andrew X. Zhu, Thomas A. Abrams, Peter C. Enzinger, Nadine J. McCleary, Deborah Schrag, Eunice L. Kwak, Jill N. Allen, Pankaj Bhargava, Jennifer A. Chan, Wolfram Goessling, Lawrence S. Blaszkowsky, Jeffrey G. Supko, (unknown), Kaori Sato, Eileen Regan, Jeffrey A. Meyerhardt, Charles S. Fuchs	38
7	Efficacy, Safety, Pharmacokinetics, and Biomarkers of Cediranib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study 2013 ·Clinical Cancer Research ·Andrew X. Zhu, Marek Ancukiewicz, Jeffrey G. Supko, Dushyant V. Sahani, Lawrence S. Blaszkowsky, Jeffrey A. Meyerhardt, Thomas A. Abrams, Nadine J. McCleary, Pankaj Bhargava, Alona Muzikansky, Susan Sheehan, Eileen Regan, (unknown), (unknown), Charles S. Fuchs, David P. Ryan, Rakesh K. Jain, Dan G. Duda	55
8	A Phase I Trial of Vorinostat and Alvocidib in Patients with Relapsed, Refractory, or Poor Prognosis Acute Leukemia, or Refractory Anemia with Excess Blasts-2 2013 ·Clinical Cancer Research ·Beata Holkova, Jeffrey G. Supko, Matthew M. Ames, Joel M. Reid, Geoffrey I. Shapiro, (unknown), Viswanathan Ramakrishnan, Mary Beth Tombes, (unknown), Renee M. McGovern, Maciej Kmieciak, Ellen Shrader, (unknown), Heidi Sankala, Austin Doyle, James R. Wright, John D. Roberts, Steven Grant	26
9	Postinduction Dexamethasone and Individualized Dosing of Escherichia Coli L-Asparaginase Each Improve Outcome of Children and Adolescents With Newly Diagnosed Acute Lymphoblastic Leukemia: Results From a Randomized Study—Dana-Farber Cancer Institute ALL Consortium Protocol 00-01 2013 ·Journal of Clinical Oncology ·Lynda M. Vrooman, Kristen E. Stevenson, Jeffrey G. Supko, Jane O’Brien, Suzanne E. Dahlberg, Barbara L. Asselin, Uma H. Athale, Luis A. Clavell, Kara M. Kelly, Jeffery L. Kutok, Caroline Laverdière, Steven E. Lipshultz, Bruno Michon, Marshall A. Schorin, Mary V. Relling, Harvey J. Cohen, Donna Neuberg, Stephen E. Sallan, Lewis B. Silverman	227
10	A Phase I First-in-Human Trial of Bardoxolone Methyl in Patients with Advanced Solid Tumors and Lymphomas 2012 ·Clinical Cancer Research ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Xiaoying He, Aung Naing, Jennifer J. Wheler, Donald P. Lawrence, Joseph P. Eder, Colin J. Meyer, Deborah A. Ferguson, James W. Mier, Marina Konopleva, Sergej Konoplev, Michael Andreeff, Donald Küfe, Hillard Lazarus, Geoffrey I. Shapiro, Bruce J. Dezube	197
11	Dependence on the MUC1-C Oncoprotein in Non–Small Cell Lung Cancer Cells 2011 ·Molecular Cancer Therapeutics ·Deepak Raina, Michio Kosugi, Rehan Ahmad, Govind Panchamoorthy, Hasan Rajabi, Maroof Alam, Takeshi Shimamura, Geoffrey I. Shapiro, Jeffrey G. Supko, Surender Kharbanda, Donald Küfe	144
12	Phase I trial with a novel orally administered synthetic triterpenoid RTA 402 (CDDO-Me) in patients with solid tumors and lymphoid malignancies 2007 ·Molecular Cancer Therapeutics ·David S. Hong, Razelle Kurzrock, Jeffrey G. Supko, Donald P. Lawrence, Jennifer Wheeler, Joseph P. Eder, (unknown), James W. Mier, Marina Konopleva, Sergej Konoplev, Sühendan Ekmekçioglu, Michael Andreeff, (unknown), Donald Küfe, Colin J. Meyer, Geoffrey I. Shapiro, Bruce J. Dezube	4
13	Efficacy and toxicity of the antisense oligonucleotide aprinocarsendirected against protein kinase C-α delivered as a 21-day continuousintravenous infusion in patients with recurrent high-grade astrocytomas 2005 ·Neuro-Oncology ·Stuart A. Grossman, Jane Β. Alavi, Jeffrey G. Supko, Kathryn A. Carson, (unknown), F. Andrew Dorr, John S. Grundy, Jon Holmlund	44
14	Phase I trial and pharmacokinetics of escalating doses of paclitaxel and concurrent hyperfractionated radiotherapy with or without amifostine in patients with advanced head and neck carcinoma 2005 ·Cancer ·Philip C. Amrein, John R. Clark, Jeffrey G. Supko, Richard L. Fabian, (unknown), A. Dimitrios Colevas, Marshall R. Posner, Daniel G. Deschler, James W. Rocco, Dianne M. Finkelstein, James McIntyre	8
15	Phase II study of liposomal doxorubicin and weekly paclitaxel for recurrent Müllerian tumors 2003 ·Gynecologic Oncology ·(unknown), Ursula A. Matulonis, Richard T. Penson, Hang Lee, Ross S. Berkowitz, Linda Duska, Arlan F. Fuller, (unknown), Thomas A. Puchalski, Jeffrey G. Supko, Michael V. Seiden	21
16	Determination of procarbazine in human plasma by liquid chromatography with electrospray ionization mass spectrometry 2003 ·Journal of Chromatography B ·Xiaoying He, (unknown), Stuart A. Grossman, Jeffrey G. Supko, (unknown)	11
17	Quantitative analysis of the novel depsipeptide anticancer drug Kahalalide F in human plasma by high‐performance liquid chromatography under basic conditions coupled to electrospray ionization tandem mass spectrometry 2002 ·Journal of Mass Spectrometry ·Ellen Stokvis, Hilde Rosing, (unknown), Ignacio Rodríguez‐García, José Jimeno, Jeffrey G. Supko, Jan H.M. Schellens, Jos H. Beijnen	42
18	Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity 2002 ·Cancer Chemotherapy and Pharmacology ·Thomas A. Puchalski, David P. Ryan, Rocio García‐Carbonero, George D. Demetri, (unknown), David C. Harmon, Michael V. Seiden, Robert G. Maki, Luis López Lázaro, José Jimeno, Cecilia Guzmán, Jeffrey G. Supko	55
19	Analysis of brefeldin A and the prodrug breflate in plasma by gas chromatography with mass selective detection 1998 ·Journal of Pharmaceutical and Biomedical Analysis ·Lawrence R. Phillips, Tracy Wolfe, Louis Malspeis, Jeffrey G. Supko	25
20	Studies on the metabolism of merbarone in man / 1988 ·OhioLink ETD Center (Ohio Library and Information Network) ·Jeffrey G. Supko	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact